Study Number	ACNS0332
Subgroup	Subset of CNS-PNET and PBL patients (n=85). A manuscript and data for the medulloblastoma patients will be forthcoming.
NCT #:	NCT00392327
PMID #:	30332335
Dataset #	1
Publication Date:	10/17/2018

For various reasons, data may contain slight discrepancies from that reported in the publication.

Variable Number	Variable Name	Variable Type	Variable Comments/Notes/Options
1	USI	Char	Universal Specimen Identifier (USI) / patient identifier
2	ACNS0332STRATUM	Char	Study Stratum M+ SPNET M0 SPNET with >1.5 cm^2 residual M0 Supratentorial PNET with < 1.5 cm^2 residual
3	dxage_yrs	Num	Age at diagnosis in years
4	onage_yrs	Num	Age at study enrollment in years
5	sex	Char	Sex M=Male F=Female
6	Race	Char	Race American Indian or Alaska Native Asian Black or African American Unknown White
7	Ethnicity	Char	Ethnicity Hispanic or Latino Not Hispanic or Latino Unknown
8	Mstage	Char	M-stage M0 M1 M2 M3
9	Mstatus	Char	Metastatic Status M+: metastatic M0: non-metastatic
10	InfraInvIndc	Num	Indicator variable for infratentorial involvement 0=No; patient did not have infratentorial involvement 1=Yes; patient had infratentorial involvement
11	PerfStatus_type	Char	Performance Status type Karnofsky Lansky
12	PerfStatus_ScoreN	Num	Performance Status Score
13	SiteOfOrigin_GH	Char	Site of Origin Note: Site of origin data were available only for patients who were phenotyped [where PhenotypedIndc=1]. The other patients have SiteOfOrigin_GH equal to “n/a”.
14	PinealIndc_GH	Num	Indicator variable for pineal involvement Note: These data were available only for patients who were phenotyped [where PhenotypedIndc=1].

			0=No; patient was phenotyped and did not have pineal involvement 1=Yes; patient was phenotyped and had pineal involvement -9=Patient was not phenotyped and data were not provided/available
15	ConsentIndc	Num	Indicator for whether or not the patient provided consent for biology studies 0=No; patient did not provide consent 1=Yes; patient provided consent
16	Slides5indc	Num	This variable denotes which patients had at least 5 slides available for DNA extraction. 1=Yes; patient had at least 5 slides available for DNA extraction 0=No; patient had less than 5 slides available for DNA extraction -9=not applicable; patient did not provide consent for biology studies
17	PhenotypedIndc	Num	Indicator Variable for whether the patient was phenotyped or not 1=Yes 0=No
18	MethPrediction	Char	Methylation Prediction Note: This variable equals "N/A" for patients who were not phenotyped [where PhenotypedIndc=0].
19	Subtype	Char	Methylation Prediction as classified into one of the following: ATRT EP GBM (=HGG) Pineal region tumors/Other supratentorial embryonal tumors Data not available
20	Group_ST3	Char	Methylation Prediction as classified into one of the following: ATRT HGG PBL RELA+ EP Supratentorial EP N/A (for patients who were not phenotyped [PhenotypedIndc=0]) ** This variable may be used for purposes of reproducing Supplemental Table 3. **
21	AnalysisGroup	Char	Analysis Group HGG: patients with a molecular diagnosis of high-grade glioma sET/PBL: patients with molecularly diagnosed supratentorial embryonal tumors without other specification or pineoblastomas Note: The variable is blank/missing for patients who were not phenotyped or for patients who were phenotyped but did not fall into one of the above two categories (for example, ATRT patients).
22	PBorET	Char	PB or ET For patients in the sET/PBL analysis group above (variable #21), this variable further subsets patients into one of the following: PB: molecularly diagnosed pineoblastoma ET: molecularly diagnosed supratentorial embryonal tumors without other specification ** This variable may be used for purposes of reproducing Supplemental Figure 4. **

			Note: The variable was provided only for patients with molecularly diagnosed supratentorial embryonal tumors without other specification or pineoblastomas [AnalysisGroup="sET/PBL"].
23	CentralRevDx_GH	Char	Central review diagnosis based on central pathology review Note: This variable equals "N/A" for patients who were not phenotyped [PhenotypedIndc=0]. ** This variable may be used for purposes of reproducing Table 1. **
24	CentralRevDxMatch	Num	Indicator for whether the central review pathology diagnosis was consistent with the methylation subgroup (used to reproduce results in Table 1) 1=Yes 0=No -9=not applicable; patient was not phenotyped
25	TreatmentGroup	Char	Treatment Group Regimen A Regimen B Regimen C Regimen D
26	CarboIndicator	Char	Variable denoting whether the patient got carboplatin or not No Carboplatin Carboplatin
27	IsotretinoinIndc	Char	Variable denoting whether the patient got Isotretinoin or not No Isotretinoin Isotretinoin
28	FU	Num	Duration of follow-up (in years) *Note: Patients still alive and event-free were included in the calculation of median follow-up and range for the overall patient population.*
29	OS	Num	Overall survival: days from enrollment to death date or date of last follow-up
30	OScen	Num	Censor indicator for overall survival 1 if patient had the event of interest (death) 0 for survivors
31	EFS	Num	Event-free survival: days from enrollment to date of first event or date of last follow-up for patients without events
32	EFScen	Num	Censor indicator for event-free survival (EFS) 1=patient had the event of interest 0=patient was event-free/censored
33	FirstEvent	Char	Type of first event: Death RL/PD (relapse/progression) SM (second malignancy) n/a (patient did not have an event)
34	RLFailPattern	Char	Failure pattern for patients with relapsed or progressive disease: Distant Local L+D (local+distant) n/a (patient did not have relapsed/progressive disease)
35	death_otherspec	Char	For patients with non-disease related deaths, this variable details the cause of death.
36	SM_hist	Char	For patients with second malignancy, this variable details the histology of the second malignancy.

37	AEindc_Blood	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this adverse event (AE) category [blood and lymphatic system disorders] (used for Supplemental Table 2) 1=Yes 0=No
38	AEindc_Cardiac	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [cardiac disorders] (used for Supplemental Table 2) 1=Yes 0=No
39	AEindc_Ear	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [ear and labyrinth disorders] (used for Supplemental Table 2) 1=Yes 0=No
40	AEindc_GI	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [gastrointestinal disorders] (used for Supplemental Table 2) 1=Yes 0=No
41	AEindc_General	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [general disorders] (used for Supplemental Table 2) 1=Yes 0=No
42	AEindc_Immune	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [immune system disorders] (used for Supplemental Table 2) 1=Yes 0=No
43	AEindc_Infection	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [infections and infestations] (used for Supplemental Table 2) 1=Yes 0=No
44	AEindc_Injury	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [injury, poisoning and procedural complications] (used for Supplemental Table 2) 1=Yes 0=No
45	AEindc_Investigations	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [investigations] (used for Supplemental Table 2) 1=Yes 0=No
46	AEindc_Metabolism	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [metabolism and nutrition disorders] (used for Supplemental Table 2) 1=Yes 0=No
47	AEindc_MSK	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [musculoskeletal and connective tissue disorders] (used for Supplemental Table 2) 1=Yes 0=No

48	AEindc_Neoplasms	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [neoplasms benign, malignant and unspecified] (used for Supplemental Table 2) 1=Yes 0=No
49	AEindc_Nervous	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [nervous system disorders] (used for Supplemental Table 2) 1=Yes 0=No
50	AEindc_Psych	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [psychiatric disorders] (used for Supplemental Table 2) 1=Yes 0=No
51	AEindc_Renal	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [renal and urinary disorders] (used for Supplemental Table 2) 1=Yes 0=No
52	AEindc_Reproductive	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [reproductive system and breast disorders] (used for Supplemental Table 2) 1=Yes 0=No
53	AEindc_Respiratory	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [respiratory, thoracic and mediastinal disorders] (used for Supplemental Table 2) 1=Yes 0=No
54	AEindc_Skin	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [skin and subcutaneous tissue disorders] (used for Supplemental Table 2) 1=Yes 0=No
55	AEindc_Surgical	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [surgical and medical procedures] (used for Supplemental Table 2) 1=Yes 0=No
56	AEindc_Vascular	Num	Indicator for whether each patient had a grade 3 or higher adverse event in this AE category [vascular disorders] (used for Supplemental Table 2) 1=Yes 0=No
57	SecPathRev_Indc	Num	An indicator variable for whether the patient was selected for a second central pathology review (10 patients were selected for pathology re-review). 1=Yes 0=No